Search

Your search keyword '"LiRADS 4, 5"' showing total 2 results
Start Over Descriptor "LiRADS 4, 5"
2 results on '"LiRADS 4, 5"'

1. De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents

Author

MarieChristi Candido, Rebecca Hluhanich, Souvik Sarkar, Gabriela Kuftinec, Thomas W. Loehfelm, Blythe Durbin-Johnson, and Michael T. Corwin

Subjects
Liver Cancer, hepatitis C virus, medicine.medical_specialty, Cirrhosis, liver-directed imaging, Hepatitis C virus, Chronic Liver Disease and Cirrhosis, medicine.disease_cause, Gastroenterology, Hepatitis, 03 medical and health sciences, Rare Diseases, 0302 clinical medicine, Hepatitis - C, Interferon, Internal medicine, medicine, In patient, direct-acting antivirals, Cancer, LiRADS 4, Hepatology, business.industry, Liver Disease, cirrhosis, Incidence (epidemiology), Evaluation of treatments and therapeutic interventions, de novo HCC, hepatocellular carcinoma, interferon, Hepatitis C, medicine.disease, digestive system diseases, Emerging Infectious Diseases, Infectious Diseases, Oncology, 6.1 Pharmaceuticals, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, Digestive Diseases, Infection, business, LiRADS 4, 5, Direct acting, Research Article, medicine.drug
Abstract

Author(s): Kuftinec, Gabriela; Loehfelm, Thomas; Corwin, Michael; Durbin-Johnson, Blythe; Candido, MarieChristi; Hluhanich, Rebecca; Sarkar, Souvik | Abstract: AimRecent studies raise concerns for higher incidence of hepatocellular carcinoma (HCC) after direct-acting antiviral therapy for hepatitis C virus (HCV).MethodsIn this study, using analysis of liver imaging pre- and post-DAA treatment, we queried new occurrence or 'de novo' of HCC in patients with HCV-cirrhosis treated with DAAs. Of 150 patients who met study criteria, 7 (4.7%; 95% CI: 2.1-9.5%) patients developed de novo HCC which did not differ from historical rates of 3% (pn=n0.22).ResultsNotably, patients with decompensated cirrhosis had significantly higher rate of de novo HCC (9.3%; 95% CI: 3.12-22.2%; pn=n0.04).ConclusionOur data support the need for continued surveillance for HCC in HCV cirrhotics even after successful therapy.

Published
2018

2. De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents.

Author

Kuftinec G, Loehfelm T, Corwin M, Durbin-Johnson B, Candido M, Hluhanich R, and Sarkar S

Abstract

Aim: Recent studies raise concerns for higher incidence of hepatocellular carcinoma (HCC) after direct-acting antiviral therapy for hepatitis C virus (HCV)., Methods: In this study, using analysis of liver imaging pre- and post-DAA treatment, we queried new occurrence or ' de novo ' of HCC in patients with HCV-cirrhosis treated with DAAs. Of 150 patients who met study criteria, 7 (4.7%; 95% CI: 2.1-9.5%) patients developed de novo HCC which did not differ from historical rates of 3% (p = 0.22)., Results: Notably, patients with decompensated cirrhosis had significantly higher rate of de novo HCC (9.3%; 95% CI: 3.12-22.2%; p = 0.04)., Conclusion: Our data support the need for continued surveillance for HCC in HCV cirrhotics even after successful therapy., Competing Interests: Financial & competing interests disclosure S Sarkar has served on advisory boards for Gilead sciences and Abbvie and received grants (paid to UC Davis) from Gilead Sciences. R Hluhanich has stocks in Gilead Sciences. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results